imaware™ Partners with Rheumatoid Patient Foundation to Promote Awareness and Early Diagnosis of Rheumatoid Arthritis
Makers of at-home health test for RA offer a $10,000 matching grant for Rheumatoid Awareness Day
HOUSTON, Jan. 29, 2019 /PRNewswire-PRWeb/ -- imaware™, an at-home testing platform for chronic illness and disease, including Rheumatoid Arthritis, designed by healthcare company Microdrop, today announced it has partnered with the Rheumatoid Patient Foundation (RPF). The newly formed partnership between the at-home testing platform and leading patient advocacy organization for people with rheumatoid disease, coincides with the 7th annual Rheumatoid Awareness Day on February 2. To further support patients and RPF's mission, imaware is sponsoring Rheumatoid Awareness Day by offering a matching grant for all donations to RPF from now through February 12, 2019, up to $10,000 USD. Donations can be made through the RPF website at: http://rheum4us.org/donate
"RPF's mission is to improve the lives of people with rheumatoid disease," said RPF Founder and President, Kelly O'Neill Young. "With the medications available today, nothing improves outcomes as much as early diagnosis and treatment. The imaware test has the potential to help millions of people have more successful treatment and a better life."
"We believe that the imaware at-home rheumatoid arthritis test will help reduce the number of undiagnosed people with RA," said Jani Tuomi, co-founder, imaware. "With a partner like the Rheumatoid Patient Foundation, we will be able to better engage with the patient community to educate, screen, and ultimately help patients engage their doctors sooner for diagnosis."
Rheumatoid arthritis, or rheumatoid disease, is a progressive inflammatory disease causing damage to joint and organ tissues, resulting in severe pain, frequent disability, and increased mortality. Rheumatoid Arthritis Day was established in 2013 by the Rheumatoid Patient Foundation as a way to address public lack of understanding of rheumatoid arthritis. The goal of the partnership is to improve speed-to-diagnosis and treatment to help those impacted by the disease to access treatment faster and improve their health outcomes.
How imaware™ Rheumatoid Arthritis test works:
Three biomarkers commonly associated with Rheumatoid Arthritis are measured: rheumatoid factors (RF) and cyclic citrullinated peptides (CCP) biomarkers. The combination of these biomarkers has been demonstrated to identify the disease in its early development, even before symptoms may show. Available online at imaware.health for $99.00 USD, the test uses a small amount of blood obtained by a finger prick and is collected in a vial. People then mail the sample back in and within five days will receive their confidential test results via a secure portal. The new imaware™ Rheumatoid Arthritis test expands upon the lineup of Celiac Disease screening and monitoring tests, and is currently available in the United States.
About the Rheumatoid Patient Foundation
The Rheumatoid Patient Foundation is a 501(c)(3) non-profit organization dedicated to improving the lives of people with rheumatoid disease. RPF was founded in 2011 to address a significant lack of disease education, comparatively low levels of research funding, and difficulty obtaining adequate treatment. RPF is committed to creating pathways to better clinical care and disease outcomes through education, awareness, and patient-centered research. For more information, visit http://rheum4us.org or follow RPF on Facebook or Twitter.
About imaware™
The imaware mission is to provide patients with the tools to drive awareness to chronic illness and empower patients to live a better and healthier life - sooner. Each imaware test is designed and validated alongside world-renowned doctors from the most prestigious medical research facilities including Dr. Timothy Niewold, Director of the NYU Colton Center for Autoimmunity, Dr. Kevin Deane, Endowed Chair for Rheumatology Research, University of Colorado Denver, Dr. Stefano Guandalini of the University of Chicago Celiac Disease Center, and Dr. Margaret Spitz and Dr. Melissa Bondy of the Dan L. Duncan Comprehensive Cancer Center at the Baylor College of Medicine. For more information, visit us online at imaware.health
SOURCE imaware
Share this article